Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit aberrantly activated pathways and/or to unleash...
Main Authors: | Gabriele Antonarelli, Federica Giugliano, Chiara Corti, Matteo Repetto, Paolo Tarantino, Giuseppe Curigliano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/9/884 |
Similar Items
-
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
by: Gihoon You, et al.
Published: (2021-07-01) -
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
by: Jing Wei, et al.
Published: (2022-10-01) -
Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
by: Christie P. M. Verkleij, et al.
Published: (2021-03-01) -
Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01) -
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
by: Giulio Cassanello, et al.
Published: (2024-12-01)